🏛️ Verified NIH Record • Updated 2026-06-11
Phenotype, Genotype & Biomarkers in ALS and Related Disorders (NCT02327845)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: University of Miami
🩺 Plain-English Summary (8th-Grade Level)
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA), and frontotemporal dementia (FTD); and (2) to develop biomarkers that might be useful in aiding therapy development for this group of disorders.
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Stanford University — Palo Alto, California
- University of California San Diego (UCSD) — San Diego, California
- California Pacific Medical Center (CPMC) — San Francisco, California
- University of Miami — Miami, Florida
- University of Iowa — Iowa City, Iowa
- Kansas University Medical Center (KUMC) — Kansas City, Kansas
- Twin Cities ALS Research Consortium — Minneapolis, Minnesota
- Wake Forest University — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- University of Texas Southwestern (UTSW) — Dallas, Texas
- University of Texas Health Science Center San Antonio (UTHSCSA) — San Antonio, Texas
- University of Virginia (UVA) — Charlottesville, Virginia
- Eberhard Karls University of Tübingen — Tübingen,
- University of Cape Town — Cape Town,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyotrophic Lateral Sclerosis
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) — Toronto, Ontario
- Regulatory T Cells for Amyotrophic Lateral Sclerosis — New York, New York
- Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) — Phoenix, Arizona
- TRIAL READY (Clinical Trial Readiness) — Miami, Florida
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment — Phoenix, Arizona
- Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS — New York, New York
Explore by condition: All Amyotrophic Lateral Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.